AMGN34.SA announced a cash dividend of 0.401 with an ex-date of Feb. 14, 2023
|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for AMGN34.SA
The stock of veteran biotech Amgen (NASDAQ: AMGN) was looking a little tired on Wednesday. The company's shares fell more than 2% in price, "thanks" to fourth-quarter results that didn't put smiles on investors' faces. In contrast to gloomy Amgen, the S&P 500 index ticked up by slightly more than 1%.
Amgen issued an outlook that discounts its looming acquisition of Horizon Therapeutics. In response, Amgen stock skidded Wednesday morning.
U.S. patients will finally get access to cheaper versions of AbbVie Inc’s blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20-year-old drug, with two tiers of pricing. One sets a 5% discount to Humira’s monthly price of $6,922.